Fed. Circ. Backs Decision Axing 4 Acorda MS Drug Patents
A split Federal Circuit panel on Monday upheld a judge's decision that four patents on Acorda Therapeutics Inc.'s multiple sclerosis drug Ampyra are invalid as obvious, clearing the way for competing...To view the full article, register now.
Already a subscriber? Click here to view full article